Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. more
Time Frame | HEPA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.81% | -2.28% | -0.57% |
1-Month Return | -8.6% | -3.98% | 1.2% |
3-Month Return | -20.27% | -9.71% | 7.56% |
6-Month Return | -50.42% | -3.39% | 11.44% |
1-Year Return | -85.18% | 3.69% | 28.47% |
3-Year Return | -97.54% | 3.78% | 29.51% |
5-Year Return | -99.45% | 39.76% | 90.64% |
10-Year Return | -100% | 106.88% | 203.73% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 26.74K | 34.52K | 86.07K | 77.46K | 67.13K | [{"date":"2019-12-31","value":31.06,"profit":true},{"date":"2020-12-31","value":40.1,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":89.99,"profit":true},{"date":"2023-12-31","value":77.99,"profit":true}] |
Gross Profit | (26.74K) | (34.52K) | (86.07K) | (77.46K) | (67.13K) | [{"date":"2019-12-31","value":-2673700,"profit":false},{"date":"2020-12-31","value":-3451500,"profit":false},{"date":"2021-12-31","value":-8607300,"profit":false},{"date":"2022-12-31","value":-7746100,"profit":false},{"date":"2023-12-31","value":-6713100,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 7.77M | 20.15M | 30.40M | 43.62M | 48.45M | [{"date":"2019-12-31","value":16.04,"profit":true},{"date":"2020-12-31","value":41.58,"profit":true},{"date":"2021-12-31","value":62.75,"profit":true},{"date":"2022-12-31","value":90.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (7.77M) | (20.15M) | (30.40M) | (45.49M) | (48.45M) | [{"date":"2019-12-31","value":-777008500,"profit":false},{"date":"2020-12-31","value":-2014607500,"profit":false},{"date":"2021-12-31","value":-3040330900,"profit":false},{"date":"2022-12-31","value":-4548872600,"profit":false},{"date":"2023-12-31","value":-4844795400,"profit":false}] |
Total Non-Operating Income/Expense | (175.94K) | (208.51K) | (2.33M) | 394.66K | (896.68K) | [{"date":"2019-12-31","value":-44.58,"profit":false},{"date":"2020-12-31","value":-52.83,"profit":false},{"date":"2021-12-31","value":-589.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-227.2,"profit":false}] |
Pre-Tax Income | (7.95M) | (20.32M) | (32.72M) | (45.08M) | (49.34M) | [{"date":"2019-12-31","value":-794602000,"profit":false},{"date":"2020-12-31","value":-2032335400,"profit":false},{"date":"2021-12-31","value":-3272216800,"profit":false},{"date":"2022-12-31","value":-4508389800,"profit":false},{"date":"2023-12-31","value":-4933506400,"profit":false}] |
Income Taxes | (908.68K) | 30.58K | 8.86K | (2.88M) | 409.02K | [{"date":"2019-12-31","value":-222.16,"profit":false},{"date":"2020-12-31","value":7.48,"profit":true},{"date":"2021-12-31","value":2.17,"profit":true},{"date":"2022-12-31","value":-705.06,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (7.04M) | (20.35M) | (32.73M) | (42.20M) | (49.74M) | [{"date":"2019-12-31","value":-703733800,"profit":false},{"date":"2020-12-31","value":-2035393800,"profit":false},{"date":"2021-12-31","value":-3273102700,"profit":false},{"date":"2022-12-31","value":-4220004900,"profit":false},{"date":"2023-12-31","value":-4974408600,"profit":false}] |
Income From Continuous Operations | (6.72M) | (20.35M) | (32.72M) | (42.20M) | (44.68M) | [{"date":"2019-12-31","value":-671869800,"profit":false},{"date":"2020-12-31","value":-2035393800,"profit":false},{"date":"2021-12-31","value":-3272216800,"profit":false},{"date":"2022-12-31","value":-4220004900,"profit":false},{"date":"2023-12-31","value":-4467788800,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (7.04M) | (20.35M) | (32.72M) | (42.20M) | (48.93M) | [{"date":"2019-12-31","value":-703733800,"profit":false},{"date":"2020-12-31","value":-2035393800,"profit":false},{"date":"2021-12-31","value":-3272216800,"profit":false},{"date":"2022-12-31","value":-4220004900,"profit":false},{"date":"2023-12-31","value":-4892604200,"profit":false}] |
EPS (Diluted) | (26.72) | (2.09) | (2.94) | (2.26) | (12.32) | [{"date":"2019-12-31","value":-2672,"profit":false},{"date":"2020-12-31","value":-209,"profit":false},{"date":"2021-12-31","value":-294,"profit":false},{"date":"2022-12-31","value":-226,"profit":false},{"date":"2023-12-31","value":-1232,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
HEPA | |
---|---|
Cash Ratio | 0.55 |
Current Ratio | 1.30 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
HEPA | |
---|---|
ROA (LTM) | -92.82% |
ROE (LTM) | -189.52% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
HEPA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.11 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.11 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
HEPA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.11 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Hepion Pharmaceuticals Inc (HEPA) share price today is $0.55
Yes, Indians can buy shares of Hepion Pharmaceuticals Inc (HEPA) on Vested. To buy Hepion Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HEPA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Hepion Pharmaceuticals Inc (HEPA) via the Vested app. You can start investing in Hepion Pharmaceuticals Inc (HEPA) with a minimum investment of $1.
You can invest in shares of Hepion Pharmaceuticals Inc (HEPA) via Vested in three simple steps:
The 52-week high price of Hepion Pharmaceuticals Inc (HEPA) is $3.72. The 52-week low price of Hepion Pharmaceuticals Inc (HEPA) is $0.48.
The price-to-earnings (P/E) ratio of Hepion Pharmaceuticals Inc (HEPA) is
The price-to-book (P/B) ratio of Hepion Pharmaceuticals Inc (HEPA) is 2.11
The dividend yield of Hepion Pharmaceuticals Inc (HEPA) is 0.00%
The market capitalization of Hepion Pharmaceuticals Inc (HEPA) is $4.11M
The stock symbol (or ticker) of Hepion Pharmaceuticals Inc is HEPA